isoflurane Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
halogenated compounds used as general inhalation anaesthetics 1493 26675-46-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • isoflurane
  • 1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether
  • forane
  • forene
  • isoforine
  • isorrane
A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
  • Molecular weight: 184.49
  • Formula: C3H2ClF5O
  • CLOGP: 1.76
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 0
  • TPSA: 9.23
  • ALOGS: -1.72
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 18, 1979 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Propofol infusion syndrome 126.51 57.83 23 2058 758 46683223
Mitochondrial DNULL mutation 122.41 57.83 19 2062 232 46683749
Intra-abdominal pressure increased 109.86 57.83 17 2064 203 46683778
Pneumatosis 105.31 57.83 18 2063 412 46683569
Gene mutation 94.72 57.83 19 2062 1061 46682920
Intestinal ischaemia 94.21 57.83 27 2054 6898 46677083
Apnoea 92.66 57.83 27 2054 7312 46676669
Status epilepticus 90.96 57.83 31 2050 13948 46670033
Hyperthermia malignant 89.06 57.83 17 2064 732 46683249
Necrosis ischaemic 87.02 57.83 17 2064 828 46683153
Blood gases abnormal 85.41 57.83 16 2065 622 46683359
Exposure during pregnancy 81.85 57.83 54 2027 108158 46575823
Delayed recovery from anaesthesia 74.62 57.83 15 2066 846 46683135
Systemic inflammatory response syndrome 68.84 57.83 20 2061 5351 46678630
Post procedural complication 68.80 57.83 26 2055 15703 46668278
Metabolic acidosis 63.34 57.83 32 2049 38748 46645233

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthermia malignant 220.62 51.89 45 1991 1789 29948653
Apnoea 111.28 51.89 33 2003 6225 29944217
Post procedural complication 98.46 51.89 35 2001 11691 29938751
Hypotension 93.03 51.89 89 1947 200476 29749966
Intestinal ischaemia 91.29 51.89 29 2007 6868 29943574
Necrosis ischaemic 87.55 51.89 15 2021 223 29950219
Superinfection 79.13 51.89 19 2017 1595 29948847
Fear 78.48 51.89 29 2007 10796 29939646
Anhedonia 74.11 51.89 26 2010 8343 29942099
Injury 71.23 51.89 33 2003 21698 29928744
Mucosal ulceration 68.02 51.89 15 2021 863 29949579
Renal injury 65.56 51.89 26 2010 11703 29938739
Systemic inflammatory response syndrome 64.38 51.89 22 2014 6524 29943918
Emotional distress 58.14 51.89 26 2010 15739 29934703

Pharmacologic Action:

SourceCodeDescription
ATC N01AB06 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Halogenated hydrocarbons
FDA EPC N0000175681 General Anesthetic
CHEBI has role CHEBI:38870 inhalation anesthetics
MeSH PA D000777 Anesthetics
MeSH PA D018685 Anesthetics, Inhalation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
FDA PE N0000175975 General Anesthesia

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Hyperkalemia contraindication 14140009
Low blood pressure contraindication 45007003
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Disease of liver contraindication 235856003 DOID:409
Malignant hyperthermia contraindication 405501007

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glycine receptor (alpha-1/beta) Ion channel POSITIVE MODULATOR CHEMBL CHEMBL
GABA-A receptor; anion channel Ion channel POSITIVE ALLOSTERIC MODULATOR CHEMBL CHEMBL
Potassium channel subfamily K member 10 Ion channel OPENER CHEMBL CHEMBL
Potassium channel subfamily K member 18 Ion channel OPENER CHEMBL CHEMBL
Potassium channel subfamily K member 3 Ion channel OPENER CHEMBL CHEMBL
Potassium channel subfamily K member 9 Ion channel OPENER CHEMBL CHEMBL
Potassium channel subfamily K member 2 Ion channel OPENER CHEMBL CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 5.11 PDSP

External reference:

IDSource
4019107 VUID
N0000147364 NUI
D00545 KEGG_DRUG
4019107 VANDF
C0022180 UMLSCUI
CHEBI:6015 CHEBI
ICF PDB_CHEM_ID
3763 PUBCHEM_CID
CHEMBL1256 ChEMBL_ID
DB00753 DRUGBANK_ID
D007530 MESH_DESCRIPTOR_UI
2505 IUPHAR_LIGAND_ID
3286 INN_ID
CYS9AKD70P UNII
6026 RXNORM
284 MMSL
4326 MMSL
4926 MMSL
d00267 MMSL
001391 NDDF
387368002 SNOMEDCT_US
66492008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
FORANE HUMAN PRESCRIPTION DRUG LABEL 1 10019-360 INHALANT 1 mL RESPIRATORY (INHALATION) NDA 22 sections
Isoflurane HUMAN PRESCRIPTION DRUG LABEL 1 12164-012 LIQUID 1 mL RESPIRATORY (INHALATION) ANDA 22 sections
Terrell HUMAN PRESCRIPTION DRUG LABEL 1 66794-011 LIQUID 1 mL RESPIRATORY (INHALATION) ANDA 13 sections
Isoflurane HUMAN PRESCRIPTION DRUG LABEL 1 66794-017 LIQUID 1 mL RESPIRATORY (INHALATION) ANDA 21 sections
Terrell HUMAN PRESCRIPTION DRUG LABEL 1 66794-019 LIQUID 1 mL RESPIRATORY (INHALATION) ANDA 21 sections
Isoflurane HUMAN PRESCRIPTION DRUG LABEL 1 66794-020 LIQUID 1 mL RESPIRATORY (INHALATION) ANDA 13 sections